PHASE-II RADIATION-THERAPY ONCOLOGY GROUP-STUDY OF HORMONAL CYTOREDUCTION WITH FLUTAMIDE AND ZOLADEX IN LOCALLY ADVANCED-CARCINOMA OF THE PROSTATE TREATED WITH DEFINITIVE RADIOTHERAPY

被引:26
|
作者
PILEPICH, MV
JOHN, MJ
KRALL, JM
MCGOWAN, D
HWANG, YS
PEREZ, CA
机构
[1] FRESNO COMMUNITY HOSP & MED CTR, FRESNO, CA USA
[2] AMER COLL RADIOL, PHILADELPHIA, PA USA
[3] SASKATOON CANC CLIN, SASKATOON, SASKATCHEWAN, CANADA
[4] BORGESS MED CTR, KALAMAZOO, MI 49001 USA
[5] WASHINGTON UNIV, ST LOUIS, MO 63130 USA
关键词
D O I
10.1097/00000421-199012000-00001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In patients with locally advanced (bulky) carcinoma of the prostate, definitive radiotherapy is associated with a high rate of local recurrence. The Radiation Therapy Oncology Group (RTOG) has conducted several studies evaluating hormonal cytoreduction (used as an induction regimen) as a means of improving the local control rate. RTOG 85-19 tested an induction regimen consisting of a depot LH-RH agonist (Zoladex) and an antiandrogen (flutamide). Eligible patients were those with bulky primary lesions (stage B2 and C) with disease confined to the pelvis. Zoladex was administered every 29 days via a subcutaneous injection. Flutamide was given by mouth in a dose of 250 mg t.i.d. Administration of the drugs was initiated 2 months prior to start of radiotherapy and was terminated at completion of the radiotherapy course. Radiotherapy consisted of 180-200 rad/day, 4,400-4,500 rad to the regional lymphatics, and 6,500-7,000 rad to the prostate. The primary aim of the study was to evaluate the effectiveness and toxicity of the combined (hormonal cytoreduction plus definitive radiotherapy) regimen. Thirty-one patients were accessioned; 30 are analyzable. The drug-related toxicity appears acceptable. It included appearance of diarrhea before initiation of radiotherapy in two patients, nausea during the 2nd week of drug administration in two patients, and skin rash in three patients. These phenomena appear to be related to flutamide. Hot flashes were recorded in 17 patients. With a minimum follow-up of 2 years, clearance of the primary lesions (by clinical examination) was documented in 28 of 30 patients. During the 1st year, two of 30 patients died (of unrelated causes) with residual palpable tumors. The observed toxicity appears acceptable and the response rate encouraging. A phase III study comparing the tested regimen against radiotherapy alone appears warranted.
引用
收藏
页码:461 / 464
页数:4
相关论文
共 50 条
  • [1] HORMONAL CYTOREDUCTION IN LOCALLY ADVANCED-CARCINOMA OF THE PROSTATE TREATED WITH DEFINITIVE RADIOTHERAPY - PRELIMINARY-RESULTS OF RTOG-83-07
    PILEPICH, MV
    KRALL, JM
    JOHN, MJ
    RUBIN, P
    PORTER, AT
    MARCIAL, VA
    MARTZ, KL
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 16 (03): : 813 - 817
  • [2] CHEMORADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA - A RADIATION-THERAPY ONCOLOGY GROUP-STUDY
    ALSARRAF, M
    PAJAK, TF
    COOPER, JS
    MOHIUDDIN, M
    HERSKOVIC, A
    AGER, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (08) : 1342 - 1351
  • [3] COMPARISON OF SPLIT-VERSUS CONTINUOUS RADIOTHERAPY IN ADVANCED-CARCINOMA OF THE URINARY-BLADDER - A RADIATION-THERAPY ONCOLOGY GROUP-STUDY
    MARCIAL, VA
    BRADY, LW
    JOHNSON, RJ
    TOME, JM
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1980, 6 : 34 - 35
  • [4] PHASE-II STUDY OF SPIROGERMANIUM IN ADVANCED ADENOCARCINOMA OF THE PROSTATE - A SOUTHWEST ONCOLOGY GROUP-STUDY
    SAIERS, JH
    BLUMENSTEIN, B
    SLAVIK, M
    COSTANZI, JH
    CRAWFORD, ED
    CANCER TREATMENT REPORTS, 1987, 71 (12): : 1305 - 1306
  • [5] PROGNOSTIC FACTORS IN LOCALLY ADVANCED-CARCINOMA OF THE CERVIX TREATED WITH RADIATION-THERAPY
    STEHMAN, FB
    THOMAS, GM
    SEMINARS IN ONCOLOGY, 1994, 21 (01) : 25 - 29
  • [6] MISONIDAZOLE AND UNCONVENTIONAL RADIATION IN ADVANCED SQUAMOUS-CELL CARCINOMA OF THE ESOPHAGUS - A PHASE-II STUDY OF THE RADIATION-THERAPY ONCOLOGY GROUP
    YDRACH, AA
    MARCIAL, VA
    PARSONS, J
    CONCANNON, J
    ASBELL, SO
    GEORGE, F
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1982, 8 (3-4): : 357 - 359
  • [7] MISONIDAZOLE AND RADIOTHERAPY TO TREAT MALIGNANT GLIOMA - A PHASE-II TRIAL OF THE RADIATION-THERAPY ONCOLOGY GROUP
    CARABELL, SC
    BRUNO, LA
    WEINSTEIN, AS
    RICHTER, MP
    CHANG, CH
    WEILER, CB
    GOODMAN, RL
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1981, 7 (01): : 71 - 77
  • [8] A PHASE-II TRIAL OF VINCRISTINE IN ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
    BROUN, GO
    BLESSING, JA
    EDDY, GL
    ADELSON, MD
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (01): : 18 - 21
  • [9] PHASE-II TRIAL OF VINBLASTINE IN ADVANCED OVARIAN-CARCINOMA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
    SUTTON, GP
    BLESSING, JA
    ADELSON, MD
    HANJANI, P
    INVESTIGATIONAL NEW DRUGS, 1990, 8 (04) : 377 - 379
  • [10] PHASE-II STUDY OF DIAZIQUONE IN UNTREATED ADVANCED GASTRIC-CARCINOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY
    PUGH, RP
    FLEMING, T
    GUY, JT
    WEICK, JK
    WARD, JH
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1989, 12 (01): : 11 - 13